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Abstract
The role of thymidylate synthase (TS) is essential as a key rate-limiting enzyme in DNA synthesis. It is the primary
target of fluorouracil and its derivates in colorectal cancer. In this study, TS mRNA expression was examined in
primary tumor and normal tissues from 76 patients with high- risk stage II/III colorectal cancer by laser capture
microdissection and polymerase chain reaction. Thirty (39.47%) patients were found to have higher TS expression
in primary tumors with earlier stage (P = 0.018), lower histological grades (P = 0.001) and high frequency
microsatellite instability (P = 0.000). Multivariate analysis showed that microsatellite instability, histological grade
and number of lymph nodes examined are independent prognostic markers.
To the editor
Adjuvant chemotherapy can prolong survival of patients
with high-risk, stage II/III colorectal cancer (CRC) after
curative surgical resection [1-3]. Thymidylate synthase
(TS) plays a major role as a key rate-limiting enzyme in
DNA synthesis and serves as the primary target of fluor-
ouracil and its derivates in CRC. It appears to have pre-
dictive and prognostic values [4,5]. Although the
differences in TS expression among primary tumors,
lymph nodes and other metastases have been reported
[6], the pattern of TS expression in normal and tumor
tissues has not been well characterized.
In this study, Laser capture microdissection (LCM)
combined with polymerase chain reaction was used to
examine TS gene expression in 76 patients with high
risk II/III stage CRC (Table 1). Microsatellite instability
(MSI, a panel of five loci recommended by National
Cancer Institute) and clinicopathological features were
analyzed at the same time.
There were 32 (42.11%) patients with differential
expression of TS gene between normal mucosa and
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Table 1 Clinicopathological Features
Features Value
Number 76
Median age, year 58 (30-65)
Male sex, % 55.26
Histological grades (%)
Low (G1 and G2) 75.00
High (G3 and G4) 25.00
Tumor Site (%) 46.8
Colon 27.63
Rectum 72.37
Staging (%)
High-risk II 65.79
III 34.21
Number of lymph node involved (%)
0 64.47
1-3 25.00
More than 3 11.00
Median number of lymph node examined 11 (6-38)
Adjuvant regimen (%)
5-fluorouracil/leucovorin 86.84
5-fluorouracil/leucovorin/oxaliplatin 13.16
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showed higher level of TS in primary tumors than in
normal tissues.
To study the significance of the differential expression
of TS in primary tumors, clinicopathological features,
including age, gender, stage, histological grade, tumor
site, and the number of lymph nodes examined, were
analyzed and compared. The results showed that higher
TS gene expression in primary tumors correlated to ear-
lier stage (stage II, P = 0.018), and lower histological
grades (G1 and G2, P = 0.001), but not to the other
parameters defined above.
MSI was also examined in these patients. High fre-
quency of MSI was found in 32.89% (25/76) of the
patients in this study. The frequency of MSI was found
to be significantly higher in patients with higher TS
gene expression than those with lower TS expression
(76.67% versus 4.35%, P = 0.000).
When the median time of relapse-free (RFS) and over-
all survival (OS) was compared, there was significant
improvement of RFS (62.80 vs 40.67 months, p = 0.030)
and OS (66.80 vs 51.67 months, p = 0.029) in patients
with higher TS expression (Figure 1). Multivariate analy-
sis was performed using a Cox regression model. MSI (P
= 0.034), histological grade (P = 0.001) and the number
of lymph nodes examined (P = 0.014) were identified as
independent prognostic markers in this study.
In summary, patients with higher TS expression in the
primary tumors, high frequency MSI, lower histological
grades and more than 10 lymph nodes examined had
better outcome after adjuvant chemotherapy.
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Figure 1 Patients with higher TS gene expression in primary tumor cells had longer median relapse-free and overall survival (P =
0.030 and P = 0.029).
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